Argenx NV, of Breda, the Netherlands, said it has recruited 50 percent of the myasthenia gravis patients in the phase II proof-of-concept study of ARGX-113, which consists of the Fc-portion of an antibody that has been modified by the company’s Abdeg technology to increase its affinity for FcRn beyond that of normal IgG antibodies.